General Information of Drug (ID: DMMSGAT)

Drug Name
BI 207127 Drug Info
Synonyms
Deleobuvir; UNII-58BU988K90; 58BU988K90; 863884-77-9; Deleobuvir [USAN:INN]; SCHEMBL900174; SCHEMBL900176; CHEMBL2403318; DTXSID40235516; BMAIGAHXAJEULY-UKTHLTGXSA-N; SB16520; BI-207127; 1221574-24-8; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic; Deleobuvir; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid; 2-Propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-, (2E)-; (E)-3-(2-(1
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 2 [1]
Cross-matching ID
PubChem CID
56948249
CAS Number
CAS 863884-77-9
TTD Drug ID
DMMSGAT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PSI-7977 DMLSUWZ HCV 1-6 infection 1E51 Approved [2]
Setrobuvir DMTNDM2 Hepatitis C virus infection 1E51.1 Phase 2 [3]
Valopicitabine dihydrochloride DMFWZ2U Virus infection 1A24-1D9Z Phase 2 [4]
INX-189 DMSTJ6Q Hepatitis C virus infection 1E51.1 Phase 2 [5]
Tegobuvir DM6YI5T Hepatitis C virus infection 1E51.1 Phase 2 [6]
VX-759 DMJUSM8 Hepatitis C virus infection 1E51.1 Phase 2 [7]
VX-135 DMZ3FE8 Hepatitis C virus infection 1E51.1 Phase 2 [8]
VX-222 DMO3U4W Hepatitis C virus infection 1E51.1 Phase 2 [7]
BMS 791325 DMKH4PI Hepatitis C virus infection 1E51.1 Phase 2 [9]
Filibuvir DMNSYXB Hepatitis C virus infection 1E51.1 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) TTMVBWH POLG_HCV1 Inhibitor [1]

References

1 2011 Pipeline of Boehringer Ingelheim Pharma.
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
4 Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.
5 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
6 Clinical pipeline report, company report or official report of Gilead (2011).
7 2011 Pipeline of Vertex.
8 All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11.
9 2011 Pipeline of Bristol-Myers Squibb.
10 Clinical pipeline report, company report or official report of Pfizer (2011).